Daphna Mokady

Title: Daphna Mokady and Retinal Disease Research.

Introduction

Daphna Mokady is an inventor based in Toronto, Canada, whose patent work focuses on potential treatments for retinal diseases. Her listed portfolio includes 3 patents, including inventions concerning compounds intended to address photoreceptor loss and degeneration of the outer retina.

Latest Patents

Mokady’s listed patent work includes “N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases.” The invention describes compounds and methods for treating retinal diseases associated with photoreceptor loss or outer-retina degeneration. It covers specified chemical structures and their pharmaceutically acceptable salts and stereochemical forms.

Another listed patent is “Compounds for use as therapeutically active substances in the treatment of retinal diseases.” It describes compounds and a method for treating retinal diseases that lead to photoreceptor loss or outer-retina degeneration. The disclosed compounds include specified oxazolyl or pyridyl groups and variations in their chemical substituents.

Career Highlights

Mokady’s patent activity reflects research into therapeutic compounds for neuroretinal conditions. The inventions described in the supplied information focus on chemical approaches to retinal disease treatment, including stimulating the production of retinal precursor cells.

Collaborations

Mokady is associated with Endogena Therapeutics, Inc. Her listed coworkers include Alex Mueller and Matthias Steger.

Conclusion

Daphna Mokady’s patent portfolio centers on potential compound-based treatments for retinal diseases, with a particular focus on photoreceptor loss and outer-retina degeneration.